Tv Therapeutics ( (VTVT)) has provided an update. On May 13, 2026, vTv Therapeutics Inc. moved to expand its financial flexibility by filing a prospectus supplement with the SEC to increase the number ...
The therapy is being examined as a potential oral adjunctive treatment to insulin for type 1 diabetes. Credit: ANDREI ASKIRKA/Shutterstock. · Clinical Trials Arena · ANDREI ASKIRKA/Shutterstock. The ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead ...
vTv Therapeutics Inc. (NASDAQ:VTVT) stock is trading lower on Monday. The FDA has placed a clinical hold on the cadisegliatin clinical program, which includes the ongoing CATT1 Phase 3 trial in type 1 ...
-Prioritization of lead program TTP399, a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients TTP399 is a novel, oral, liver-selective ...
CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months vTv Therapeutics expects to resume the trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results